Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Top Page
Larimar Therapeutics
(NASDAQ:LRMR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.00
▼(-0.79% Downside)
Action:ReiteratedDate:03/20/26
Score is held back mainly by weak financial performance (no revenue, sharply rising losses and cash burn, and equity erosion). Offsetting factors include favorable corporate catalysts (Breakthrough Therapy Designation and a targeted 2026 BLA timeline) plus improved liquidity from recent financing, while technicals are mixed with neutral momentum and a potentially oversold signal.
Positive Factors
Regulatory progress: Breakthrough Therapy
Receiving Breakthrough Therapy Designation and FDA alignment on a skin frataxin surrogate endpoint materially strengthens Larimar's regulatory pathway. This structural de-risking supports an accelerated BLA timeline and could shorten time to market if confirmatory data meet requirements, making the program persistently more attractive to stakeholders and partners.
Negative Factors
Pre-revenue, widening losses
Larimar remains a pre-revenue R&D-stage company with sharply widening annual losses. Persistent negative profitability means ongoing reliance on external capital to fund development. If clinical or regulatory setbacks occur, funding needs will rise, increasing dilution risk and undermining long-term financial sustainability absent a clear path to product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: Breakthrough Therapy
Receiving Breakthrough Therapy Designation and FDA alignment on a skin frataxin surrogate endpoint materially strengthens Larimar's regulatory pathway. This structural de-risking supports an accelerated BLA timeline and could shorten time to market if confirmatory data meet requirements, making the program persistently more attractive to stakeholders and partners.
Read all positive factors
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$523.57M
Dividend YieldN/A
Average Volume (3M)7.47M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS Growth-67.41%
CountryUS
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding103,882,935
10 Day Avg. Volume1,921,236
30 Day Avg. Volume7,465,820
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.34K
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$13.90Price Target Upside175.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.96
Revenue Forecast (FY)N/A
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinic...
How the Company Makes Money
Larimar Therapeutics is a clinical-stage company and, as such, it generally does not generate recurring revenue from commercial product sales because it does not have an approved product on the market. Its ability to fund operations is therefore t...
Larimar Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -350.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -172.50M | -90.57M | -41.45M | -36.21M | -50.14M |
| Net Income | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | |||||
| Total Assets | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | |||||
| Free Cash Flow | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Positive
5.04
Price Trends
4.23
Positive
3.90
Positive
3.85
Positive
Market Momentum
0.10
Positive
58.59
Neutral
83.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Positive. The current price of 5.04 is above the 20-day moving average (MA) of 4.74, above the 50-day MA of 4.23, and above the 200-day MA of 3.85, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 58.59 is Neutral, neither overbought nor oversold. The STOCH value of 83.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 80 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Larimar Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $440.35M | -2.36 | -49.24% | ― | 11.12% | -406.76% | |
53 Neutral | $790.52M | -325.70 | 1.71% | ― | ― | 12.32% | |
52 Neutral | $523.57M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $362.57M | -7.84 | -51.44% | ― | ― | 68.53% | |
45 Neutral | $291.74M | -4.58 | 105.48% | ― | -3.91% | 37.89% | |
44 Neutral | $387.75M | -1.23 | -113.81% | ― | ― | 20.71% |
* Healthcare Sector Average
LRMR
Larimar Therapeutics
5.04
3.33
194.74%
OMER
Omeros
10.98
4.95
82.09%
VNDA
Vanda
7.45
3.31
79.95%
FHTX
Foghorn Therapeutics
4.97
1.76
54.83%
CADL
Candel Therapeutics
4.95
0.55
12.50%
NMRA
Neumora Therapeutics, Inc.
2.13
1.41
195.83%
Larimar Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
Positive
Mar 9, 2026
On March 9, 2026, Larimar Therapeutics posted an updated corporate presentation outlining progress in its nomlabofusp program for Friedreich’s ataxia and ongoing regulatory engagement. The company reported that the FDA has granted nomlabofus...
Private Placements and Financing
Larimar Therapeutics Announces Upsized Public Equity Offering
Positive
Feb 27, 2026
On February 25, 2026, Larimar Therapeutics, Inc. entered into an underwriting agreement with a syndicate led by J.P. Morgan Securities LLC and Guggenheim Securities, LLC for a public offering of 20,000,000 shares of its common stock at $5.00 per s...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp
Positive
Feb 24, 2026
On February 24, 2026, Larimar Therapeutics said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its lead candidate nomlabofusp for treating adults and children with Friedreich’s ataxia, reflecting preliminar...
Private Placements and FinancingRegulatory Filings and Compliance
Larimar Therapeutics executes preferred stock exchange and amendment
Neutral
Jan 22, 2026
On January 21, 2026, Larimar Therapeutics entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP under which the investor agreed to swap 2.5 million shares of Larimar common stock for 250,000 shares of t...
Business Operations and StrategyProduct-Related Announcements
Larimar advances nomlabofusp toward accelerated Friedreich’s ataxia approval
Positive
Jan 12, 2026
On January 12, 2026, Larimar Therapeutics posted an updated corporate slide deck outlining the progress of its lead candidate nomlabofusp toward registration as what it positions as the first potential disease-modifying therapy for Friedreich̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.